Literature DB >> 30883196

Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.

Daesik Kim1, Kevin Luk2, Scot A Wolfe2, Jin-Soo Kim1,3.   

Abstract

Programmable nucleases and deaminases, which include zinc-finger nucleases, transcription activator-like effector nucleases, CRISPR RNA-guided nucleases, and RNA-guided base editors, are now widely employed for the targeted modification of genomes in cells and organisms. These gene-editing tools hold tremendous promise for therapeutic applications. Importantly, these nucleases and deaminases may display off-target activity through the recognition of near-cognate DNA sequences to their target sites, resulting in collateral damage to the genome in the form of local mutagenesis or genomic rearrangements. For therapeutic genome-editing applications with these classes of programmable enzymes, it is essential to measure and limit genome-wide off-target activity. Herein, we discuss the key determinants of off-target activity for these systems. We describe various cell-based and cell-free methods for identifying genome-wide off-target sites and diverse strategies that have been developed for reducing the off-target activity of programmable gene-editing enzymes.

Entities:  

Keywords:  CRISPR/Cas9; Cas12a; Cpf1; base editors; gene editing; off-target

Mesh:

Substances:

Year:  2019        PMID: 30883196     DOI: 10.1146/annurev-biochem-013118-111730

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  39 in total

Review 1.  Allosteric regulation of CRISPR-Cas9 for DNA-targeting and cleavage.

Authors:  Zhicheng Zuo; Jin Liu
Journal:  Curr Opin Struct Biol       Date:  2020-02-18       Impact factor: 6.809

2.  Identifying genome-wide off-target sites of CRISPR RNA-guided nucleases and deaminases with Digenome-seq.

Authors:  Daesik Kim; Beum-Chang Kang; Jin-Soo Kim
Journal:  Nat Protoc       Date:  2021-01-18       Impact factor: 13.491

Review 3.  CRISPR technologies for precise epigenome editing.

Authors:  Muneaki Nakamura; Yuchen Gao; Antonia A Dominguez; Lei S Qi
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

4.  Systematic identification of plausible pathways to potential harm via problem formulation for investigational releases of a population suppression gene drive to control the human malaria vector Anopheles gambiae in West Africa.

Authors:  John B Connolly; John D Mumford; Silke Fuchs; Geoff Turner; Camilla Beech; Ace R North; Austin Burt
Journal:  Malar J       Date:  2021-03-29       Impact factor: 2.979

5.  CRISPR-based functional evaluation of schizophrenia risk variants.

Authors:  Prashanth Rajarajan; Erin Flaherty; Schahram Akbarian; Kristen J Brennand
Journal:  Schizophr Res       Date:  2019-07-03       Impact factor: 4.939

Review 6.  High-throughput methods for genome editing: the more the better.

Authors:  Yong Huang; Meiqi Shang; Tingting Liu; Kejian Wang
Journal:  Plant Physiol       Date:  2022-03-28       Impact factor: 8.340

Review 7.  Advances in genome editing for genetic hearing loss.

Authors:  Ning Ding; Sangsin Lee; Matan Lieber-Kotz; Jie Yang; Xue Gao
Journal:  Adv Drug Deliv Rev       Date:  2020-05-07       Impact factor: 15.470

Review 8.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 9.  Tools for experimental and computational analyses of off-target editing by programmable nucleases.

Authors:  X Robert Bao; Yidan Pan; Ciaran M Lee; Timothy H Davis; Gang Bao
Journal:  Nat Protoc       Date:  2020-12-07       Impact factor: 13.491

10.  Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.

Authors:  Mitchell L Leibowitz; Stamatis Papathanasiou; Phillip A Doerfler; Logan J Blaine; Lili Sun; Yu Yao; Cheng-Zhong Zhang; Mitchell J Weiss; David Pellman
Journal:  Nat Genet       Date:  2021-04-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.